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Abstract 
Background: This study aimed to synthesize the existing evidence on the efficacy and safety of a single dose arte-
misinin–naphthoquine (ASNQ) for treatment of uncomplicated malaria in endemic countries.
Methods: A meta-analysis of randomized, controlled trials (RCT), assessing efficacy and safety of single dose ASNQ 
was carried out. Comparator drugs included artemether–lumefentrine (AL), chloroquine plus sulfadoxine-pyrimeth-
amine (CQSP) and dihydroartemisinin–piperaquine (DHP). The efficacy and safety profile of non-comparator, single-
arm studies on the single dose ASNQ was also assessed. The primary endpoint was efficacy defined as an absence of 
PCR-confirmed parasitaemia. The methodological quality of the included studies was assessed using the six domains 
for the risk of bias.
Results: Five RCTs and three single-arm studies were included in this review. As RCT studies did not compare the 
same anti-malarial drugs, it was difficult to do a pooled analysis. At day 28, a pooled analysis of two RCTs (n = 271) 
showed a comparable efficacy on PCR-confirmed parasitaemia between ASNQ and AL. Another RCT, which com-
pared ASNQ and CQSP or ASNQ and DHP, also showed comparable efficacy. At day 42, one RCT comparing ASNQ and 
DHP and another RCT comparing ASNQ and AL reported comparable levels of efficacy. The proportion of parasite 
clearance was faster in the ASNQ groups than the comparators at day 1, and almost all parasites were cleared by day 3 
in the ASNQ groups.
Conclusions: The present review provides some evidence to support that there is similar efficacy and safety of the 
single dose ASNQ compared to other anti-malarial drugs in treating uncomplicated malaria. Larger, adequately pow-
ered, well-designed studies are recommended to substantiate the efficacy and safety in different populations and in 
different epidemiological settings. As the potential evolution of drug resistance is a great concern and this cannot be 
addressed in a short-term study, the use of single dose ASNQ needs further evaluation.
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Background
The target set under Millennium Development Goal 
6 will be reached by 55 countries that are on track to 
reduce their malaria burden by 75  % [1]. Despite pro-
gress in the reduction of malaria morbidity and mortal-
ity in recent years, malaria remains one of the leading 
health problems in endemic countries. It has been esti-
mated that there were 198 million (124–283 million) 
cases of malaria and 584,000 (136,000–755,000) deaths 
from malaria worldwide in 2013. The vast majority of 
cases (90 %) occurred in the African region [1]. Being a 
curable disease, early diagnosis and prompt treatment is 
a key strategy to reduce morbidity and mortality from 
malaria. A core component of any malaria elimination 
programme is to ensure that all patients with malaria 
are rapidly diagnosed, have access to highly effective 
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anti-malarial drugs and are able to complete the course 
of treatment [2].
The development of resistance to conventionally used 
anti-malarial drugs, such as chloroquine (CQ) and sulf-
adoxine-pyrimethamine (SP) has been documented [3]. 
WHO recommended that artemisinin-based combination 
therapy (ACT) should be used for treating uncomplicated 
Plasmodium falciparum malaria to ensure efficacy and 
reduce the emergence of drug-resistant parasites [1, 4, 5]. 
Since 2007, WHO had recommended that oral artemisinin 
monotherapy should be gradually phased out and replaced 
with ACT [1]. The concept of combination therapy relies 
on the rapid onset of schizonticidal action [6, 7] to rapidly 
reduce parasitaemia, leaving the residual parasitaemia to 
be cleared by high concentrations of the partner drug [8].
Resistance of malaria parasites to currently used ACT 
has emerged and is following a similar pattern of resist-
ance previously observed with other anti-malarial drugs. 
Thus far, studies have documented evidence of P. falci-
parum resistance to artemisinin (the key component of 
all ACT) in five countries of the Greater Mekong Sub-
region, such as Cambodia, Laos, Myanmar, Thailand, and 
Vietnam [1] and this was confirmed on the Cambodia-
Thailand border [4]. Thus, it is crucial to monitor the 
efficacy and safety of newly formulated ACT in view of 
artemisinin resistance.
A recent development of an oral single dose ACT ther-
apy is a coformulated combination of artemisinin and 
naphthoquine phosphate (NQ) [6, 7, 9]. NQ is absorbed 
rapidly and completely after oral administration, and 
reaches peak plasma concentration 2–4  h after admin-
istration [6, 10, 11]. It has a long elimination half-life 
greater than 255  h [12]. Its partner drug, artemisinin is 
a short-acting drug with elimination half-life of 0.87 
(±SD 0.23) h [13]. With due attention to evidence of arte-
misinin resistance, artemisinin–naphthoquine (ASNQ) 
and any ACT which has a component of artemisinin are 
subject to concerns on rational use and efficacy.
Individual studies assessing efficacy and safety of 
the single dose ASNQ are available. As transmission of 
malaria varies even over small distances [14], informa-
tion from clinical studies across endemic countries is of 
immense value. Thus, it is deemed worthwhile to aggre-
gate the efficacy and safety of single dose ASNQ com-
pared to commonly (and currently) used anti-malarial 
regimens. Taken together, the objective of the present 
study was to synthesize existing evidence on the efficacy 
and safety of single dose ASNQ for treatment of uncom-
plicated malaria in endemic countries.
Methods
The present study adhered to the preferred report-
ing items for systematic reviews and meta-analyses 
(PRISMA) [15]. The standard methods of systematic 
review of clinical studies as described in the Cochrane 
Systematic Review Handbook were applied [16].
Study search
Studies on the assessment of efficacy of single dose 
ASNQ in treating uncomplicated malaria were searched 
in electronic databases such as MEDLINE, EMBASE, 
CINHAL and the Cochrane Library. For ongoing and 
unpublished trials, the websites of WHO, the clinical tri-
als database, and the drug manufacturer were checked. 
The reference sections of the selected studies and rel-
evant reviews were also checked for the possibility of any 
additional papers. The search was limited to human stud-
ies, published in English, French and Chinese languages 
until May 2015. Medical subject headings (MeSH) terms 
and text words were (artemisinin–naphthoquine OR 
ARCO) AND (treatment success OR treatment failure 
OR efficacy OR tolerability OR safety) AND (malaria OR 
uncomplicated malaria OR asymptomatic malaria OR 
Plasmodium OR falciparum OR vivax).
Study selection
Studies following the PICOS criteria [15] were included.
Participants (P) Participants residing in endemic coun-
tries and having uncomplicated malaria, regardless of 
age, gender, pregnancy status, and species of malaria 
parasite were considered. Diagnosis of malaria was based 
on microscopy of Giemsa-stained peripheral blood films 
or a rapid-onsite diagnostic test. Subsequent PCR-based 
analysis for species confirmation was an additional merit.
Intervention (I) Studies using fixed combination sin-
gle dose ASNQ by participants in one arm, regardless of 
route of administration and brand name were considered.
Comparison (C) Studies which compared the efficacy 
of single dose ASNQ to alternative anti-malarial drug(s) 
or placebo were included.
Outcomes (O) For simplicity sake, the primary and sec-
ondary outcomes were efficacy and safety, respectively. 
Efficacy was defined as the proportion of absence of (1) 
PCR-confirmed parasitaemia in patients at day 28 and 
at day 42, (2) PCR-unconfirmed parasitaemia in patients 
at day 28 and at day 42, or, (3) parasitological and fever 
clearance time. The safety outcomes were incidence of 
adverse events (AEs) and serious adverse events (SAEs). 
Studies were included if the effect estimates of each study 
such as relative risk (RR), odds ratio (OR) or hazards ratio 
(HR) and its 95 % confidence interval (CI) were provided 
or made available for computation.
Study design (S) Randomized controlled trials (RCTs) 
which assessed efficacy of fixed-combination single dose 
ASNQ in treating uncomplicated malaria were included. 
Information from single-arm trials were also considered 
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separately for the therapeutic efficacy of ASNQ, although 
they were not included in the main meta-analysis. 
Abstracts and conference reports were included, if they 
provided adequate data on the comparable efficacy 
between single dose ASNQ and other anti-malarial 
drug(s).
Data extraction
Two authors independently screened the title and abstract 
yielded from the electronic search. Any discrepancies 
between the two authors were resolved by consensus. The 
two authors individually collected information from each 
included study using the piloted data extraction form. 
Information collected included characteristics of partici-
pants, study design, characteristics of the experimental 
drug (dosage, route of administration, brand of ASNQ), 
confirmation of malaria infection, specific speciation, 
duration of follow-up and the reported clinical outcomes. 
For studies with overlapping of study population, the one 
that provided the most comprehensive data was used.
The methodological quality of the included studies 
was assessed using the risk of bias tool applied for the 
Cochrane systematic reviews [16]. The six domains for the 
risk of bias: random sequence generation, allocation con-
cealment, blinding of outcome assessment, incomplete 
outcome data adequately addressed, free of suggestion of 
selective outcome reporting and other sources of poten-
tial bias addressed. Any discrepancies between the two 
authors were resolved by discussion. Analysis was done 
on an intention-to-treat (ITT) basis, whenever possible.
Statistical analysis
RR and its 95  % CI for dichotomous data and/or mean 
difference (MD) and standard deviation (SD) for con-
tinuous data from each study were recorded. Meta-anal-
ysis was performed, if two or more studies with direct 
head-to-head comparisons were included. This was 
only possible for the comparison between ASNQ and 
artemether–lumefantrine (AL) due to limited number of 
studies in the similar manner. Initially, it was planned to 
stratify analyses by the targeted malaria parasite (P. fal-
ciparum, Plasmodium vivax, mixed malaria infection), 
transmission intensity, brand and dosing of ASNQ. Due 
to an insufficient number of studies and paucity of data, 
stratification was not possible.
Sensitivity analysis was not done because of the lim-
ited number of studies. Data analysis was performed with 
RevMan 5·3 [17]. The protocol of the current review is 
registered with PROSPERO [18].
Results
The process of study selection is presented in Fig.  1. 
The initial search yielded 404 citations. Of these, 19 
studies that assessed the efficacy and safety of ASNQ 
were potentially eligible based on titles and abstracts 
[6, 7, 10, 11, 19–33]. Eleven full-text studies were then 
removed as they were not appropriate. A final of five 
RCTs [19–23] and three non-comparative single-arm 
studies [6, 10, 11] were identified for the current review. 
A conference abstract [20] was included among these as 
its complementary information was available in another 
publication [24]. One study each was published in Chi-
nese [6] and in French [21], while the rest were in Eng-
lish. Four of the five RCTs reported data on the treatment 
efficacy on day 28 [19, 21–23], while two trials on day 42 
[20, 22]. All three single-arm studies reported data at day 
28 [6, 10, 11].
Eleven full-text studies were excluded because they (1) 
overlapped with a study included in this review [7], (2) 
assessed ASNQ plus another drug [25], (3) had multiple 
doses of ASNQ [26, 27], (4) were dose comparisons [28, 
29], (5) were reviews [24, 30], (6) were a pharmacokinetic 
study [31], and, (7) not assessed with single dose regimen 
[32, 33]. A summary of these excluded studies is provided 
in Additional file 1.
Characteristics of the included studies
Only five RCTs and three single-arm studies were iden-
tified for the current review. The characteristics of the 
included RCTs are provided in Additional file  2. Of the 
five RCTs in the current review, one study each was car-
ried out in Benin [21], Indonesia [22], Nigeria [23], Papua 
New Guinea (PNG) [19], and Uganda [20]. In the present 
review, single dose ASNQ was compared to AL in three 
studies [20, 21, 23], CQ plus SP (CQSP) in one study [19] 
and dihydroartemisinin–piperaquine (DHP) in another 
study [22]. One single-arm study was done in China [6], 
Myanmar [11] and Sudan [10] (Table  1). All five RCTs 
assessed both efficacy and safety outcomes. Most of 
the RCTs (80  %; 4/5) reported the clinical and labora-
tory parameters of the participants [19, 21–23]. Less 
than half of the RCTs (40 %; 2/5) provided PCR-adjusted 
parasitaemia [21, 22]. Two RCTs [19, 21] and two single-
arm studies [10, 11] were funded by the drug manufac-
turer, Kunming Pharmaceutical Corp (KPC). Two RCTs 
revealed that the authors had no conflicts of interest [22] 
and/or the drug manufacturer had no role in the plan-
ning, protocol design and execution of the study [19].
Methodological quality (Table 2)
Overall, most of the RCTs (80 %, 4/5) included in the cur-
rent review had ‘low risk of bias’ as they met five of the 
six domains assessed [19, 21–23]. These clinical trials 
differed in sample size from 97 [23] to 401 participants 
[22]. The majority of RCTs in this review (60 %, 3/5) were 
blinded [20–22] or were open-label studies [19, 22, 23]. 
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(n = 76) 
Records excluded  
(n =57) 
Full-text articles 
assessed for eligibility  
(n =19) 
excluded, with reasons 
(n =11); 
Overlapped data [1], 
ASNQ plus another drug 
[1], multiple doses of 
ASNQ[2],dose comparison 
[2], reviews [2],  
pharmacokinetic study 
[1], not with single dose 
regimen [2]. Studies included in 
synthesis  
(n = 8) 
Fig. 1 PRISMA flow diagram indicating the process of study selection
Table 1 Characteristics of the single-arm studies included in the review
ART artemisin; ASNQ artemisinine-naphthoquine; Co-NQ artemisinine-naphthoquine; FCT fever clearance in hour; KPC Kunming Pharmaceutical Corporation, China; 
NA not available; PCT parasite clearance in hour; tabs tablets
a Compared with artemisinine alone or naphthoquine alone
Study author, year 
of publication  
[reference]
Country Main parasite 
species
Drug  
schedule
Brand  
(manufacture)
Dosing 28 day cure 
rate, n (%)
PCT FCT
Wang et al., 2003 [6] China P. falciparum Single dosea Co-NQ (KPC) 8 Tabs (1000 mg 
ART + 400 mg 
NQ)
97/100 (97) 30 ± 8 17.5 ± 12.3
Nour et al., 2013 [10] Sudan P. falciparum Single dose ARCO (KPC) 8 Tabs (1000 mg 
ART + 400 mg 
NQ)
120/122 (98.4) 34.8 ± 12.6 12 ± 4.8
Tun et al., 2009 [11] Myanmar P. falciparum Single dose ASNQ (KPC) 52/53 (98.1) 34.6 ± 14.3 18.2 ± 8.6
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This implied both the research investigator and the patient 
could be aware of the type of treatment that the patient was 
receiving. Only one study [22] provided the sample size 
calculation, showing adequate power to detect significant 
differences between the two treatment arms of the study. 
Two RCTs were superiority trials, assessing whether ASNQ 
was more effective than DHP [22] or AL [23]. All these five 
RCTS reported ITT. While the ITT approach is not ideal, 
it is considered to be the most appropriate approach for 
superiority trials since the ITT principle implies a conserv-
ative effect on the outcome of the trial [34]. Two clinical tri-
als also reported per protocol analysis [22, 23].
Efficacy
As the RCTs included in the present review did not com-
pare ASNQ with the same anti-malarial drugs, it was dif-
ficult to do a pooled analysis. At day 28, a pooled analysis 
of two RCTs (n = 271) showed a similar efficacy between 
ASNQ single dose (94.2  %, 130/138) and AL (94  %, 
125/133) (RR: 0.99, 95  % CI 0.96–1.02; I-square value: 
0 %) [21, 23]. Of note, parasitaemia in the Nigeria study 
was not confirmed by PCR [23]. Also, a comparable effi-
cacy was reported between ASNQ single dose (95.5  %, 
192/201) and DHP (92.5 %, 186/201) (RR: 1.03, 95 % CI 
0.98–1.08) [22] on PCR-confirmed parasitaemia, and 
between ASNQ single dose (94.1  %, 48/51) and CQSP 
(87.8  %, 43/49) on PCR-unconfirmed parasitaemia (RR: 
1.07, 95 % CI 0.95–1.22) [19] (Fig. 2).
At day 42, there was a similar efficacy between ASNQ 
(90 %, 181/201) and DHP (90 %, 180/200) on PCR-con-
firmed parasitaemia (RR: 1.0, 95  % CI 0.94–1.07) [22] 
and between ASNQ (98.2  %, 111/113) and AL (98.2  %, 
110/112) on PCR-confirmed parasitaemia (RR: 1.0, 95 % 
CI 0.97–1.04) [19] (Fig. 3). Due to a paucity of data, strat-
ify analysis by malaria parasite speciation was not possi-
ble. All single-arm studies were assessed on patients with 
P. falciparum malaria.
Parasite and fever and clearance time (hours)
The mean parasite clearance time (PCT) was comparable 
between ASNQ (28 ± 11.7) and DHP (25.5 ± 12.2) (MD: 
2.5, 95  % CI 0.16–4.64) [22]. The proportion of parasite 
clearance in the first three days is shown in Table 3. Among 
adults with malaria, the odds of reduction in parasite 
clearance within the initial 24  h in the ASNQ group was 
1.2 times faster than that in the CQSP [19] or DHP [22]. 
Almost all parasitaemia was cleared by day 3 [19, 21–23].
Fever clearance time (FCT) was reported in two RCTs; 
a comparable FCT was shown between ASNQ and DHP 
(MD: 1.7, 95  % CI −0.05 to 3.45) [20] or ASNQ and 
CQSP (MD: −3.6, 95 % CI −7.42 to 0.22) [19].
Gametocytaemia
Only one RCT reported this data. The gametocytaemia 
by day 3 was reduced from 67.3 to 18.6 % in ASNQ and 
from 70.3 to 17 % in DHP (p > 0.05) [22]. A single-arm 
study reported that no gametocytes were detected in the 
blood smears examined [10].
Adverse events
In all five RCTs, AEs were recorded and compared 
between treatment groups (i.e., single dose ASNQ group 
vs comparator group). Table  4 provides the list of AEs 
in the included RCTs. Due to inconsistency in report-
ing it was difficult to undertake the pooled estimates of 
AE incidence. The most commonly reported AEs, which 
Table 2 Review authors ‘judgment on the risk of bias of included trials
‘Yes’ indicates ‘low risk of bias; ‘No’ indicates ‘high risk of bias’; ‘Unclear’ indicates ‘uncertain risk of bias’
a Included all expected outcomes
b Mean parasite counts at baseline are significantly different between the two arms
c Described as sufficient sample
Description of domains Author, publication year [reference no.]
Hombhanje et al.,  
2009 [19]
Rujumba et al.,  
2010 [20]
Kinde-Gazard et al.,  
2012 [21]
Tjitra et al.,  
2012 [22]
Udoh et al., 
2014 [23]
Random sequence generation Yes Unclear Yes Yes Yes
Allocation concealment Open label Unclear Yes Open label Open label
Blinding of outcome assessment Unclear Yes Yes Yes Unclear
Incomplete outcome data  
adequately addressed
Yes Unclear Yes Yes Yes
Free of suggestion of selective  
outcome reportinga
Yes Unclear Yes Yes Yes
Addressed other sources  
of potential bias
Yes Yes Yesb Yes Yes
Sample size calculation Yesc No No Yes Yes
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were assumed to be drug-related were nausea, vomiting, 
itchiness, transient deafness, and skin rashes.
Sensitivity analyses
Per protocol analysis, all patients who were not available 
(e.g., those withdrawn, lost to follow-up) were removed 
from the denominator, and this was done in two RCTs 
[22, 23]. At day 28, one RCT reported a comparable effi-
cacy between ASNQ (87 %, 47/54) and AL (81.4 %, 37/43) 
on PCR-unconfirmed parasitaemia (p = 0.88) [23]. At day 
42, another RCT reported a comparable efficacy between 
ASNQ and DHP (96.3 vs. 97.3  %; p: 0.56) on PCR-con-
firmed parasitaemia [22]. Due to the limited number of 
studies, sensitivity analysis was not performed. Publica-
tion bias was not investigated as the minimum recom-
mended number of studies required to perform this is ten 
[16].
Discussion
In order to facilitate the development of treatment poli-
cies for the deployment of effective anti-malarial drugs, 
a systematic monitoring of anti-malarial drug efficacy 
and drug resistance is needed [5, 34]. The present study 
reviews the efficacy and safety of the newly co-formulated 
single dose ASNQ in treating uncomplicated malaria in 
endemic countries.
Efficacy
Overall, the findings could provide some evidence that 
there was a comparable efficacy between ASNQ sin-
gle dose and comparators such as CQSP, DHP and AL. 
Moreover, the efficacy estimates of ASNQ were consist-
ent at day 28 and at day 42. Using both day 28 and day 
42 in this analysis was relevant because a 28-day follow-
up captured the majority of treatment failures with drugs 
inclusive of artemisinin derivatives, while the longer 
follow-up for 42  days was optimal for these drugs [35]. 
RCTs, as well as single-arm studies, showed ≥95  % of 
therapeutic efficacy, which is a desirable level recom-
mended for a new drug by the WHO [36].
A pooled analysis of studies assessing artesunate–
amodiaquine including a single dose regimen in treating 
uncomplicated malaria documented that rapid P. falcipa-
rum clearance continued to be achieved in sub-Saharan 
African patients treated with ACT [37].
Parasite clearance
The current analysis showed that ASNQ single dose had 
a property of rapid reduction in parasite biomass within 
the initial 24 h. In fact, the rate at which treatment clears 
parasites within the first few days is the most useful prac-
tical test for ACT. This is because early response to treat-
ment relies predominantly on the parasite response to 
AL: artemether-lumefantrine; ASNQ: artemisinin-naphthoquine;  CQ-SP: chloroquine plus 
sulfadoxine-pyrimethamine ; Risk ratio > 1 indicates better efficacy
Fig. 2 Comparative efficacy between artemisinin–naphthoquine and comparators at day 28
Page 7 of 11Naing et al. Malar J  (2015) 14:392 
artemisinin, independent of whether parasites are later 
cleared permanently through the combination of longer-
lived companion drug and the host’s immune response 
[38].
Reduction of gametocytaemia
Although ACT reduced the density of gametocytaemia 
and the proportion of infected mosquitoes, sub-micro-
scopic levels of gametocytes (which were present in a 
significant number of patients after treatment) appeared 
to be sufficient to drive post-treatment transmission [39]. 
The detection of gametocytes by microscopy represents 
only the ‘tip of the iceberg’. Therefore, relying only on 
gametocyte carriage as an indicator can result in an over-
estimation of the effects of treatment regimens [19].
Safety measure
One of the key elements in any drug development and 
evaluation is the issue of safety for the population for 
whom the drug is intended [25]. The incidence of AEs 
in the included studies was presented in various ways 
due to inconsistency in the symptoms reported or actual 
variation in the symptoms attributed to the drug. This 
created difficulties in pooling the results. A study in 
AL: artemether-lumefantrine; DHP: dihydroartemisinin-piperaquine;  
ASNQ: artemisinin-naphthoquine; Risk ratio > 1 indicates better efficacy
Fig. 3 Comparative efficacy between artemisinin–naphthoquine and comparators at day 42
Table 3 Clearance of blood parasites in the first 3 days
PNG Papua New Guiana
a Adapted from Fig. 1 [21]
b Adapted from Fig. 4 [22]
Study author, publica-
tion year [reference]
Country Targeted popu-
lation
Main parasite 
species
Drug (n) Day 1 (odds 
ratio)
Day 2 (odds ratio) Day 3 (odds 
ratio)
Hombhanje et al., 2009 
[19]
PNG Adults P. falciparum ASNQ (51) 94 % 99.8 % 99.95 %
CQSP (49) 79 % (1.18) 99.3 % (≈1.0) 99.7 % (≈1.0)
Rujumba et al., 2010 [20] Uganda Children P. falciparum ASNQ NA 100 % NA
AL 100 % (1.0)
Kinde-Gazard et al., 2012a 
[21]
Benin Children P. falciparum ASNQ (84) 98 % 100 % 99.5 %
AL (90) 96 % (1.02) 99 % (1.02) 100 % (1.01)
Tjitra et al., 2012b [22] Indonesia Adults P. falciparum ASNQ (201) 70 % 98 % 100 %
DHP (201) 58 % (1.2) 98 % (1.0) 100 % (1.0)
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Nigeria [28] compared three ASNQ treatment regimens 
in ≥15-year-old children (n = 121), comparing four tab-
lets as a single dose (700  mg, group A), eight tablets as 
a double dose (1400 mg, group B) and eight tablets as a 
single dose (1400  mg, group C). Treatment success was 
not significantly different among these three groups. 
The occurrence of a blister on the lips was reported in 
a patient receiving the double dose of ASNQ, but not in 
patients receiving the single dose [29]. This can reflect 
potential problems of tolerability with the double dose. 
Further careful monitoring of ASNQ-related AE and 
dose response effects are needed. ASNQ-related SAEs 
were not reported in any of the studies included in the 
current review.
Schedule of therapy
A study assessing a dose comparison of ASNQ in chil-
dren with malaria showed similar efficacy and tolerability 
between single dose with water/with milk and twice daily 
dose regimens, indicating single dosing can be expected to 
improve better compliance [28]. A shorter regimen, such 
as single dose coformulated drug (ASNQ in this case), is 
usually better than a three-day regimen for ideal compli-
ance (to the treatment schedule) [11]. Although any of the 
current regimens could be given for 1 day only the three-
day regimens were considered. In the three-day regimen, 
the artemisinin component is present in the body for a 
short enough time to cover only two asexual parasite life 
cycles, except in the case of Plasmodium malariae. In 
each cycle, artemisinin and its derivatives would reduce 
parasite biomass by a factor of ~10,000 [19, 40].
A dose range study in PNG showed that a lower sin-
gle ASNQ dose was associated with relatively frequent 
recurrence of P. vivax infections [28]. The recommended 
ACT (for instance, AL, artesunate-mefloquine) follows 
three-day treatment regimens. A clinical trial showed 
that the three-day ASNQ was non-inferior to AL for the 
treatment of uncomplicated falciparum malaria among 
young children in PNG and had greater efficacy than AL 
against vivax malaria [32, 33].
Any anti-malarial regimen must have robust evidence 
of both optimal efficacy for patient survival and an abil-
ity to reduce the potential for drug resistance [19]. The 
findings of this review, based on available data, showed 
evidence on the efficacy and tolerability of the ASNQ sin-
gle dose. Continuous monitoring of parasite resistance to 
this ASNQ is still needed.
Study limitations
There are limitations to the present study. A small num-
ber of studies with small samples on the assessment of the 
ASNQ single dose were identified for the present review. 
In order to demonstrate the non-inferiority (by a margin 
of 5 %) of an alternative treatment (ASNQ in this case) to 
a current treatment known to be 95 % effective, at least 
299 patients would be necessary in each study arm, with 
a one-sided test that has a statistical power of 80 % and 
a significance level of 2.5 % [41]. Using the best efficacy 
data (e.g., 100 % in ASNQ and 98.7 % in comparator) and 
the same 5 % non-inferiority margin, type 1 error prob-
ability and power as in the original sample size estimates, 
the total of 52 participants would be required to show 
non-inferiority for this primary endpoint [32]. If so, all 
five RCTs [19–23] seemed to be sufficient to define the 
efficacy in two groups. However, the PNG study [19] had 
reported efficacy in the ASNQ (94  %) and comparator 
Table 4 Distribution of adverse events in the studies
AL arthemether-lumefantrine (Coartem), ASNQ artemisinin–naphthoquine single dose, CQ chloroquine, DHP dihydroartemisinin–piperaquine, SP sulphadoxine-
pyrimethine, NA not available/not mention
Study author, publication  
year [reference]
Sample size  
(ASNQ/comparator)
Comparator  
drug
Study  
country
ASNQ group Comparator group
Hombhanje et al., 2009 [19] 51/49 CQ-SP PNG Transient deafness: 7.8 % Transient deafness: 2 %
Itchiness: 2 % Itchiness: 4 %
Skin rash: 2 % Skin rash: 2 %
Dark urine: 2 % Dark urine: 0 %
Vomiting: 2 % Vomiting: 4.1 %
Rujumba et al., 2010 [20] 113/112 AL Uganda NA NA
Kinde-Gazard et al., 2012 [21] 84/90 AL Benin Nausea: 9.5 % Nausea: 7.8 %
Itchiness: 2.3 % Itchiness: 2.2 %
Abdominal: pain: 6.3 % Abdominal: pain: 5.5 %
Tjitra et al., 2012 [22] 201/200 DHP Indonesia Nausea: 57 % Nausea: 54 %
Headache: 55 % Headache: 55 %
Udoh et al., 2014 [23] 43/54 AL Nigeria Transient maculopapular rash: 
0.23 %
None
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(80  %), hence, the required sample size was 348, which 
was about 3.5 times higher than the reported total of 100 
participants.
The PCR-confirmation of parasites was done in only 
two RCTs in the current review [21, 22], hence, the 
chance of diagnostic bias is a concern. This was more 
prominent in areas where P. falciparum and P. vivax 
co-exist. For instance, the efficacy of ASNQ and CQSP 
were comparable in the PNG study where P. falcipa-
rum and P. vivax are equally important [19]. Thus, P. 
vivax was likely to be missed in PCR-uncorrected para-
sitaemia. This could be more pronounced in the CQSP 
group as parasite resistance to this combination drug is 
already confirmed in PNG [19]. The efficacy reported in 
the PNG study, therefore, needs to be interpreted in the 
light of these important biases. Moreover, PCR is useful 
for classification of re-infection or recrudescence. Hence, 
misclassification bias is a concern in the absence of PCR 
confirmation.
Three RCTs in this review were open-label trials [19, 
22, 23]. As both the research investigator and the patient 
could be aware of the type of treatment this might lead to 
reporting bias of AEs in open-label trials [42]. Further-
more, true anti-malarial drug resistance may not be the 
same as treatment failure. If the administration of anti-
malarial drug does not reach a sufficient blood concen-
tration level, it will cause an inability to clear parasites in 
that malaria episode [1, 43]. Due to a lack of information 
on blood concentrations of the drugs administered, the 
current findings should be interpreted with a high degree 
of caution.
Due to limited data, the current review is unable to pro-
vide evidence for different age groups or different Plas-
modium species. All single-arm studies were conducted 
on patients having P. falciparum [6, 10, 11]. It is likely that 
studies which were not published in the peer-reviewed 
literature might have been missed. However, not being in 
peer-reviewed literature raises questions about the qual-
ity of the study and its evidence. Another concern is that 
an assessment of therapeutic efficacy between ASNQ and 
CQSP [19] needs caution as CQ is a relatively old drug 
with known resistance by P. falciparum.
Public health implications
Based on available data, the current analysis shows com-
parable efficacy and safety profiles of the single dose 
ASNQ. Single dose ASNQ can improve treatment com-
pliance and is simple and practicable. This is because this 
single dose can be delivered as directly observed treat-
ment, immediately after confirmation of malaria [11]. 
Should mass drug administration be required in an out-
break of malaria, the (ASNQ) single dose could be a key 
element in community deployment of ACT. However, a 
single dose (even with a repeated dose on day 2) is insuf-
ficient as it can expose only one asexual cycle to the arte-
minisin component. Although a high cure rate could be 
attained from an ACT containing an effective partner 
drug, this will not provide sufficient protection from drug 
resistance [44]. In fact, malaria parasites will be elimi-
nated, and the patient cured, if the plasma concentration 
of the free anti-malarial drug (ASNQ in this case) still 
exceeds the concentrations required to maintain the par-
asite multiplication rate below one (the minimum inhibi-
tory concentration) [45]. The risk of the development of 
de novo resistance is increased with the duration of time 
the dividing asexual parasites are exposed to drugs. This 
makes the long-term risk of developing resistance a con-
cern for single dose ACT [22]. As the ultimate goal of 
combination therapy is to prevent resistance developing, 
the usefulness of single dose ASNQ for treating uncom-
plicated malaria in endemic countries needs further 
evaluation.
The relatively long terminal half-life and wide thera-
peutic index of NQ [29] could contribute to better effi-
cacy in three-day ASNQ regimen. This is because NQ 
can suppress the re-appearance of both P. falciparum 
and P. vivax for a longer period than piperaquine and, in 
particular lumefantrine. This is because the peak plasma 
concentration of benflumetol (i.e., the chemical name for 
lumefantrine) is attained slowly (8  h plus a 2-h absorp-
tion lag time), and the elimination half-life is estimated 
to be 4.5 days [46]. Although the resistance mechanisms 
of NQ are unknown, there is a potential for it to develop 
cross-resistance between NQ and CQ (both are 4-ami-
noquinoline derivatives) and a slight cross-resistance 
between NQ and artemisinin, lumefantrine or pyrimeth-
amine (these drugs are unrelated to NQ both chemically 
and in terms of mechanism of action). The decreasing 
efficacy of amodiaquine single-agent treatment have been 
reported in some sub-Saharan African settings. If arte-
misinin resistance occurs there, it is expected to result 
soon in treatment failures, particularly in semi-immune 
populations such as children in high-transmission areas 
or patients of all ages in low transmission areas [37]. 
There is no study on single dose ASNQ with special 
groups such as pregnant women and infants and these 
are still needed.
Conclusions
The present review provide some evidence to support the 
comparable efficacy and safety of the single dose ASNQ 
compared to other comparator anti-malarial drugs in 
treating uncomplicated malaria. Larger, adequately pow-
ered, well-designed studies are recommended to sub-
stantiate the efficacy and safety in different populations 
and in different epidemiological settings. As the potential 
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evolution of drug resistance is a great concern and this 
cannot be addressed in a short-term study, the use of sin-
gle dose ASNQ needs further evaluation.
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